新型纳米抗体在肌无力症患者中显示出前景
Nanobody Shows Promise in Myasthenia Gravis
PREVAIL III期试验显示,新型纳米抗体gefurulimab在肌无力症患者中显著改善症状,且安全性与安慰剂相当。该药每周一次皮下注射,方便患者使用,且与IVIG兼容,可能改变治疗方式。
研究显示新药在MG患者中有效且安全性良好,可能改变治疗方式。
— PREVAIL trial found rapid improvement with a once-weekly subcutaneous injection
by Gregory Laub, Senior Director, Video, MedPage Today
November 10, 2026 • 3 min read
Results from the phase III PREVAIL trial presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that treatment with the investigational once-weekly nanobody gefurulimab significantly improved symptoms in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, with a safety profile generally comparable to placebo.
In this exclusive MedPage Today video, James Winkley, MD, of Baptist Health Medical Group in Lexington, Kentucky, discusses the findings, including the potential convenience of self-administered treatment with the subcutaneous injectable and compatibility with intravenous immunoglobulin (IVIG) therapy.
Following is a transcript of his remarks:
The PREVAIL study was a double-blind, placebo-controlled trial with gefurulimab as the treating agent. Gefurulimab is a unique agent in that it's the first nanobody that'll be used in myasthenia gravis, which makes it a smaller molecule, which allows for greater tissue penetration and solubility -- so it can be given as a [subcutaneous] injection rather than the larger monoclonal antibodies, which have to be given in larger volumes underneath the skin or as IV infusion. So this would represent a greater ease of access for patients to have a [subcutaneous], once-a-week injection that doesn't require them to go to the infusion center.
As we had seen in the trial, similar to eculizumab [Bkemv] and ravulizumab [Ultomiris], which are C5 inhibitors, it met its primary outcome of MG-ADL [Myasthenia Gravis Activities of Daily Living] reduction, with a minus 4.2 reduction versus 2.1 on placebo, which was statistically significant. We did see a quick onset of action within 1 week, with a statistically significant reduction in the MG-ADL for those patients, as well as 4 weeks for the [Quantitative Myasthenia Gravis].
There were similar side effects between the treatment group and the placebo group, with injection-site reactions being slightly higher in the treatment group, but all of those reactions tended to be mild to moderate. The most common adverse events were headaches, upper respiratory infections, and muscle aches and pains. One thing that was significant at any time we're using complement inhibitors, there were no meningococcal infections. Everybody made sure they were fully vaccinated, and if they'd had to be started prior to 2 weeks, they received antibiotics. But we had a very typical safety profile, as I said, between the placebo arm and the treatment arm -- the side effects were similar.
This is going to make for ease of access for patients. You still have other molecules out on the market. You've got a once-daily complement inhibitor and you've got now a once-every-2-weeks IV infusion versus every 8 weeks. So kind of depending on what the patient prefers, this gives them greater access. We've got an easily portable complement inhibitor that patients no longer are tethered to an infusion center that they have to worry about. When's our next infusion? Do I have access? And I think that's going to be a huge advantage for the patients and their quality of life.
I would say that one thing that's unique about [gefurulimab] is that it is compatible with IVIG. And so the other larger monoclonal antibodies like the FcRn [neonatal Fc receptor] and the larger eculizumab and ravulizumab, it gets recycled by a different mechanism because it goes through the albumin on the FcRn receptor. It was combined with IVIG during the trial, patients could be on stable dosages of it, so it has that advantage of being able to be compared and not have to give supplemental dosing.
So I think that it will have combination with other available medications. I think that's a big advantage for it.
来源:MedPage Today · medpagetoday.com